Dr. Anne Carol Goldberg presented at a Late-Breaking Clinical Trial session at the American College of Cardiology’s ACC.19 on March 18 in New Orleans. Her presentation concerning the results of the CLEAR Wisdom trial covered the benefits of adding bempedoic acid to statins to further reduce LDL-C in patients with hypercholesterolemia.
Goldberg and others hypothesized that bempedoic acid might promote further LDL-C reductions in patients who must limit their statin dose or who cannot tolerate statins.
“These findings indicate that this agent may add to the armamentarium of treatment options for high-risk patients with atherosclerotic cardiovascular disease whose LDL cholesterol remains uncontrolled despite taking a maximally tolerated statin,” Goldberg said.
